HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dysken, M. Articles by The Ondansetron Study Group, Search for Related Content PubMed PubMed Citation Articles by Dysken, M. Articles by The Ondansetron Study Group,

Ondansetron in the Treatment of Cognitive Decline in Alzheimer Dementia

Received January 20, 2001; revised April 26, 2001; accepted May 16, 2001. From the Geriatric Research, Education, and Clinical Center (11G), Minneapolis VA Medical Center, Minneapolis, MN. Address correspondence to Dr. Dysken, Geriatric Research, Education, and Clinical Center (11G), One Veterans Drive, Minneapolis, MN 55417.

The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 µg/day and 100 µg/ day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.

Key Words: Alzheimer Disease Treatment • Ondansetron • 5-HT3 antagonists